1 <u>Title</u>

- 2 Histology of type 3 macular neovascularization and microvascular anomalies in treated
- 3 age-related macular degeneration: a case study

4 Authors

- 5 Andreas Berlin MD MS,^{1,2} Diogo Cabral MD,^{3,4} Ling Chen, MD PhD,^{1,5} Jeffrey D
- 6 Messinger DC,¹ Chandrakumar Balaratnasingam MD PhD,⁶⁻⁸ Randev Mendis MD,⁹
- 7 Daniela Ferrara MD PhD,¹⁰ K. Bailey Freund MD,^{3,11} Christine A Curcio PhD^{1*}
- 8
- 9 ¹ Department of Ophthalmology and Visual Sciences, School of Medicine, University of
- 10 Alabama at Birmingham, Birmingham AL, USA;² Department of Ophthalmology,
- 11 University Hospital Wu Irzburg, Wu Irzburg, Germany; ³ Vitreous Retina Macula
- 12 Consultants of New York NY, USA; ⁴ NOVA Medical School Research, Universidade
- 13 NOVA de Lisboa, Portugal; ⁵ The First Affiliated Hospital of Chongqing Medical
- 14 University, Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute,
- 15 Chongqing, China; ⁶ Centre for Ophthalmology and Visual Science, University of
- 16 Western Australia, Perth, Australia; ⁷ Lions Eye Institute, Nedlands, Western Australia,
- 17 Australia; ⁸ Department of Ophthalmology, Sir Charles Gairdner Hospital, Western
- 18 Australia, Australia; ⁹ Canberra Retina Center, Canberra Australia, ¹⁰ Genentech, South
- 19 San Francisco, CA, USA; ¹¹ Department of Ophthalmology, New York University
- 20 Grossman School of Medicine, New York NY, USA
- 21
- 22 *Corresponding author

23

- 24 Short title Intraretinal vascular morphologies in treated AMD
- 25 Word count 4007
- 26 **Figures 11**
- 27 **Tables** 2
- 28 **Supplementary** 5 figures, 1 video, 2 tables
- 29 **Corresponding Address**
- 30 Christine A. Curcio, PhD; Department of Ophthalmology and Visual Sciences; EyeSight
- 31 Foundation of Alabama Vision Research Laboratories; 1670 University Boulevard Room
- 32 360; University of Alabama at Birmingham, School of Medicine; Birmingham AL 35294-
- 33 0099; Email: <u>christinecurcio@uabmc.edu</u>

34 Key words

- 35 age-related macular degeneration, type 3 macular neovascularization, deep retinal age-
- 36 related microvascular anomalies, vascular morphology, optical coherence tomography
- 37 angiography, histopathology, electron microscopy.
- 38
- 39

Intraretinal vascular morphologies in treated AMD

40 Abstract

41 **Objective/Purpose**

- 42 To investigate intraretinal neovascularization and microvascular anomalies by correlating
- 43 in vivo multimodal imaging with corresponding ex vivo histology in a single patient.
- 44 Design
- 45 A case study comprising clinical imaging from a community-based practice, and
- 46 histologic analysis at a university-based research laboratory (clinicopathologic
- 47 correlation).

48 **Participants**

- 49 A white woman in her 90's treated with numerous intravitreal anti-vascular endothelial
- 50 growth factor (VEGF) injections for bilateral type 3 macular neovascularization (MNV)
- 51 secondary to age-related macular degeneration (AMD).

52 Intervention(s)/ Methods

- 53 Clinical imaging comprised serial infrared reflectance, eye-tracked spectral-domain
- 54 optical coherence tomography (OCT), OCT angiography, and fluorescein angiography.
- 55 Eye tracking, applied to the two preserved donor eyes, enabled correlation of clinical
- 56 imaging signatures with high-resolution histology and transmission electron microscopy.
- 57 Main Outcome(s) and Measure(s)
- 58 Histologic/ ultrastructural descriptions and diameters of vessels seen in clinical imaging.
- 59 Results
- 60 Six vascular lesions were histologically confirmed (type 3 MNV, n=3; deep retinal age-
- 61 related microvascular anomalies (DRAMA), n=3). Pyramidal (n=2) or tangled (n=1)
- 62 morphologies of type 3 MNV originated at the deep capillary plexus (DCP) and extended
- 63 posteriorly to approach without penetrating persistent basal laminar deposit. They did
- 64 not enter the sub-retinal pigment epithelium (RPE)-basal laminar space or cross Bruch's
- 65 membrane. Choroidal contributions were not found. The neovascular complexes

Page 3 of 32

Intraretinal vascular morphologies in treated AMD

66	included pericytes and non-fenestrated endothelial cells, within a collagenous sheath
67	covered by dysmorphic RPE cells. DRAMA lesions extended posteriorly from the DCP
68	into the Henle fiber and the outer nuclear layers, without evidence of atrophy, exudation,
69	or anti-VEGF responsiveness. Two DRAMA lacked collagenous sheaths. External and
70	internal diameters of type 3 MNV and DRAMA vessels were larger than comparison
71	vessels in the index eyes and in aged normal and intermediate AMD eyes.
72	Conclusions
73	Type 3 MNV vessels reflect specializations of source capillaries and persist during anti-
74	VEGF therapy. The collagenous sheath of type 3 MNV lesions may provide structural
75	stabilization. If so, vascular characteristics may be useful in disease monitoring in
76	addition to fluid and flow signal detection. Further investigation with longitudinal imaging
77	before exudation onset will help determine if DRAMA are part of the type 3 MNV
78	progression sequence.
79	
80	

81 Abbreviations

82 AMD, age-related macular degeneration; BLamD, basal laminar deposit; BrM, Bruch's 83 membrane; ChC, choriocapillaris; Ch, choroid; DCP, deep capillary plexus; DRAMA, 84 deep retinal age-related microvascular anomalies; ELM, external limiting membrane; 85 ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; GCL, 86 ganglion cell layer; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform 87 layer; IS, inner segment; MNV, macular neovascularization; nvAMD, neovascular age-88 related macular degeneration; OCT, optical coherence tomography; OCTA, optical 89 coherence tomography angiography; ONL, outer nuclear layer; OPL, outer plexiform 90 layer; OS, outer segment; RPE, retinal pigment epithelium.

Intraretinal vascular morphologies in treated AMD

92 Introduction

93 Type 3 macular neovascularization (type 3 MNV) is a subtype of neovascular agerelated macular degeneration (AMD).¹ Unlike type 1 MNV, which arises from the choroid, 94 type 3 MNV originates in the neurosensory retina.^{2, 3} Female gender, older age, and 95 96 presence of subretinal drusenoid deposits confer risk for type 3 MNV.^{4, 5} Type 3 MNV is 97 diagnosed in a third of Caucasian patients presenting with unilateral neovascular AMD⁶ 98 and may be underestimated overall. Fellow eyes often convert to neovascular AMD 99 within 3 years.⁷⁻⁹ Early lesions respond well to intravitreal anti-vascular endothelial growth factor (VEGF) therapy, unlike chronic lesions.^{2, 10} New information about type 3 100 101 MNV and related vascular anomalies from histopathology, as provided herein, could 102 support improved detection and treatment decisions in affected patients. 103 Recent clinical imaging studies have elucidated type 3 MNV pathophysiology. 104 Three stages are defined based on structural optical coherence tomography (OCT). 105 Precursors to Stage 1 are hyperreflective foci (HRF) at the level of the deep capillary 106 plexus (DCP), often near drusen. Stage 1 includes an intraretinal hyperreflective lesion 107 and cystoid macular edema. In Stage 2, outer retinal disruption appears. At Stage 3, the 108 hyperreflective lesion extends into the sub-RPE basal lamina (BL) space, associated 109 with a pigment epithelium detachment.² By color fundus photography, fluorescein 110 angiography (FA), and OCT, type 3 MNV exhibit a specific regional distribution and 111 pattern of hemorrhage.¹¹⁻¹³ Lesions localize preferentially to the inner ring of the Early 112 Treatment of Diabetic Retinopathy Study (ETDRS) grid. Flame-shaped intraretinal 113 hemorrhages are located over type 3 MNV lesions, pointing toward the fovea. OCT 114 angiography (OCTA) with 3-dimensional reconstruction and display shows vertically 115 oriented components of type 3 MNV. Using this technology, Borelli et al describe two 116 morphologic phenotypes ('filiform' and 'saccular') of advanced type 3 MNV.¹⁴

Intraretinal vascular morphologies in treated AMD

117	Prior clinicopathological correlation has elucidated some cellular detail
118	corresponding to the OCT-based stages. ^{15, 16} Neovascular complexes originating at the
119	DCP have a vertical and downward trajectory. These complexes expand posteriorly and
120	cross persistent basal laminar deposit (BLamD) to enter the sub-RPE-BL space. Some
121	complexes appear like base-down pyramids that are ensheathed by collagenous
122	material. ^{3, 16} Participatory cells include macrophages, VEGF-positive fibroblasts,
123	lymphocytes, Müller cell processes, and subducted RPE cells. ^{15, 16} Hence, ischemia and
124	inflammation may promote the development and progression of type 3 MNV. ^{15, 16}
125	Microvascular abnormalities involving the DCP include microaneurysms,
126	telangiectasia, perifoveal exudative anomalous vascular complex (PEVAC), and capillary
127	macroaneurysms. ¹⁷⁻²² PEVAC was initially described in non-AMD eyes as an isolated
128	aneurysmal dilation of a retinal capillary originating between the superficial and deep
129	plexuses, with exudation that is unresponsive to anti-VEGF. ^{17, 22, 23} Deep retinal age-
130	related microvascular anomalies (DRAMA) are recently proposed as DCP alterations in
131	the setting of AMD findings like soft drusen and intraretinal HRF. Eyes with DRAMA
132	show abnormal horizontal or vertical vessels with a diameter of >50 μm and/or a location
133	below the posterior border of the outer plexiform layer (OPL) . ²⁴ In contrast to type 1
134	MNV, ²⁵ precursors, early stages, and potential masqueraders for type 3 MNV, which
135	may include DRAMA, are not described at the histologic level. ²⁶ Human eyes with
136	longitudinal clinical imaging are especially valuable sources for such information. ³
137	Herein we directly compared longitudinal OCT and angiographic signatures of
138	intraretinal neovascularization and microvascular anomalies to corresponding histology.
139	We analyzed both eyes of a single patient who had received intravitreal anti-VEGF
140	treatments for type 3 MNV over the course of 5 years (right eye) and 9 months (left eye).
141	

Intraretinal vascular morphologies in treated AMD

143 Methods

144 <u>Compliance</u>

145 Approval for this study was obtained by Institutional review at the University of

- 146 Alabama at Birmingham (protocol #300004907). The study was conducted in
- 147 accordance with the tenets of the Declaration of Helsinki and the Health Insurance
- 148 Portability and Accountability Act of 1996.^{27, 28}

149 <u>Clinical course</u>

150 A white, pseudophakic woman in her 90's received comprehensive

151 ophthalmologic examination and multimodal imaging during a 5-year follow-up for

152 bilateral type 3 MNV secondary to AMD. The patient presented 5 years prior to death

153 with exudative type 3 MNV in the right eye. Over 5 years, she received a total of 37

154 intravitreal anti-VEGF injections over approximately 6 fluid resorption cycles in the right

eye (12 x 0.5 mg/ 0.05 ml ranibizumab then 25 x 2 mg/ 0.05 ml aflibercept). One fluid

156 resorption cycle is defined as the time in weeks and the number of injections needed

157 from initial detection of intraretinal/ subretinal edema on OCT until complete absence of

edema on OCT. The left eye was diagnosed with exudative type 3 MNV 4 years after the

159 right eye. Over 9 months, the left eye received a total of 6 intravitreal anti-VEGF

160 injections over approximately 2 fluid resorption cycles (12 x 0.5 mg/ 0.05 ml

161 ranibizumab). Her general medical history included dyslipidemia and paroxysmal atrial

162 fibrillation. Six months before death, the patient was diagnosed with gallbladder

adenocarcinoma. Her last anti-VEGF treatment before death due to adenocarcinoma

164 was 3 and 2 months for the left and right eye, respectively.

165 <u>Clinical image capture and analysis</u>

166 All images were acquired using Spectralis HRA+OCT (Heidelberg Engineering,

167 Heidelberg, Germany). Available for review were 11 (right eye) and 7 (left eye) eye-

168	tracked spectral domain OCT volumes (6 mm x 6 mm horizontal and radial scans; 20° x
169	20° field). FA was available for both eyes at first presentation and 4 years later.
170	One eye-tracked spectral domain OCTA volume (3 mm x 3 mm horizontal scans, 256 B-
171	scans at 6 μ m spacing, 10° x 10° field, ART 5, quality 34 dB) was obtained of the right
172	eye 3.5 years after presentation. ²⁹ An investigational version of Heidelberg Eye Explorer
173	(v. 6.16.100.701, Heidelberg Engineering, Heidelberg, Germany) was used for analysis,
174	processing, and post-processing of data. ^{3,30} Projection artifact was removed via 3-
175	dimensional vessel-shape estimation and a Gaussian blur filter. ^{3, 30} Raw (floating point)
176	data were exported as a .VOL file.
177	Volume rendering enhances visualization of type 3 MNV, which is vertically
178	oriented, and allows afferent/ efferent vascular connections to be identified, particularly
179	in deeper retinal layers. ^{3, 31} To visualize lesions at different angles of rotation, OCTA B-
180	scans were first processed using linear quadratic estimation (noise variance estimate of
181	0.05 and a gain of 0.8; MATLAB version R2019b, Natick, Massachusetts: The
182	MathWorks Inc.; 2019), followed by volume rendering and analysis (Imaris v9.5, Bitplane,
183	Andor Technology plc.). ³² The Filament Tracer tool was used to trace superficial arteries
184	and veins after evaluation of dye circulation in FA. Video recording and still images were
185	annotated to highlight structural and flow details.
186	Previous reports indicated both eccentricity- and hemifield-dependent
187	asymmetries in the spatial distribution of type 3 MNV. ^{11, 12, 33} Thus, for potential
188	mechanistic insight into tissue-level associations, location of vascular lesions was
189	documented. Lesion distance from the fovea was calculated using the OCT volume and
190	NIR en face image using a custom ImageJ plug-in 'Spectralis Browser OCT', available at
191	https://sites.imagej.net/CreativeComputation/. Meridional position was documented
192	using the sectors of the ETDRS grid. ^{34,35}

Intraretinal vascular morphologies in treated AMD

193

194 <u>Histology preparation and image analysis</u>

As described, ³⁶ globes were recovered 2:05 hours after death and preserved in 195 196 buffered 1% paraformaldehyde and 2.5% glutaraldehyde. Pre-mortem eve-tracked OCT 197 volumes were registered to post-mortem OCT volumes of the same globes.³⁷ For high-198 resolution histology over large areas, a rectangular tissue block containing fovea and 199 optic nerve was post-fixed in 1% osmium - tannic acid - paraphenylenediamine and 200 embedded in epoxy resin. A tissue block 8 mm x12 mm wide was processed for stepped 201 sections at 30-60 µm intervals. Interleaved 30 µm-thick slabs were re-embedded for 202 transmission electron microscopy (TEM). Sub-micrometer sections stained with toluidine blue were scanned using a 60X oil immersion objective.³⁸ Tissue sections on 112 (right 203 204 eye) and 87 (left eye) glass slides spanning a distance of 5453 µm (right eye) and 4243 205 um (left eye) centered on the two foveas were matched to clinical OCT scans by 206 comparing overall tissue contours.

DRAMA vessels are defined by a diameter criterion (>50 µm),²⁴ and our previous 207 208 and current observations indicated that a collagenous sheath surrounds type 3 MNV 209 neovessels. Further, OCTA shows only the moving blood cell column and not the 210 collagenous sheath. Therefore, we manually measured internal (luminal) and external 211 cross-sectional diameters of vessels ('oval' tool, FIJI Is Just: ImageJ 2.0.0-rc- 69/1.52p; 212 www.fiji.sc;). Type 3 MNV vessels meandered over several glass slides, and sections on 213 each slide were measured. To contextualize neovessel measurements, DCP vessels on 214 either side of the area directly involved in exudation in the index case were also 215 measured. Further, vessels aligned along the outer border of the INL of intermediate 216 AMD eves and age-similar controls (n= 8 each) on the Project MACULA website of AMD histopathology were also measured.²⁵ Because vessels could run longitudinally within a 217

Intraretinal vascular morphologies in treated AMD

- section, we report a minimal cross-section diameter (approximated by Feret diameter in
- 219 ImageJ for ellipses). Due to small numbers, these data were not analyzed statistically.

Intraretinal vascular morphologies in treated AMD

221 Results

- 222 **Table S1** lists all figures to provide an overview.
- 223 Classification of lesions and longitudinal clinical imaging
- 224 We first classify vascular complexes in the two eyes at one time point, then
- 225 describe them in longitudinal clinical imaging and detailed histology. Table 2 lists
- hyperfluorescent lesions seen by FA 11 months before death (Figure 1). Six of 7 lesions
- localized to the inner ring of the ETDRS grid (0.5-1.5 mm eccentricity), with the seventh
- at 1.52 mm. There was no predilection for any one sector. Six of 7 lesions were
- confirmed as vascular by histology, and the seventh (Figure S2) could not be found.
- Lesion morphology was categorized as tangled type 3 MNV (n=1), pyramidal type 3
- 231 MNV (n=2), or DRAMA (n=3). As seen previously, ^{3, 16} pyramidal type 3 MNV was
- 232 defined as a focal, vertically extending neovessel complex. Tangled type 3 MNV was
- 233 defined as a horizontally extending neovessel complex. DRAMA was defined as
- anomalous vascular elements extending posterior to the DCP and into the HFL/ONL, i.e.,
- anterior to the ELM.²⁴ Hyperfluorescent lesions in the right eye due to window defects
- 236 were reported elsewhere.³⁹

At initial presentation 5 years before death, the right eye exhibited multiple instances of MNV secondary to AMD with multifocal leakage on FA (**Figure S3**). At this time, fluid was not detected in the left eye (**Figure S4**). Four years later and 11 months before death (**Figure 1**), the left eye was diagnosed with exudative type 3 MNV due to AMD. By this time, the right eye had received 32 intravitreal anti-VEGF injections at intervals of 4-8 weeks resulting in 4 fluid resorption cycles.

243 Pyramidal (OD 2, OS 4) and tangled (OD 1) type 3 MNV

244 Pyramidal type 3 MNV (OS 4) closely resembles previously described OD 2⁴ in

- terms of location, OCT appearance, and histologic features (Figure 1, Figure 5, Figure
- **6**, respectively). In brief, OS 4 is a vertically oriented, pyramidal-shaped, intraretinal

Intraretinal vascular morphologies in treated AMD

247	lesion located in the nasal sector of the ETDRS inner ring, with heterogeneous
248	hyperreflectivity on OCT (Figure 5). On histology, this lesion corresponds to a collagen-
249	ensheathed neovascular complex that extends from the OPL/INL border through the
250	HFL /ONL (Figure 6A). The complex is flanked by RPE cells that extend off the top of
251	the pyramid and along a DCP vessel (Figure 6B). The pyramid base adheres to
252	denuded and persistent BLamD, which drapes a calcified druse (Figure 6A&B). ⁴ The
253	vessel did not enter the subRPE-BL space, and no choroidal contribution was found.
254	Transmission electron microscopy of this pyramidal lesion reveals endothelial
255	cells and pericytes (Figure 7A). Endothelial cells are not fenestrated (Figure 7B), like
256	endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris (Figure
257	7C&D). Other vessel wall components, e.g., smooth muscle cells, connective tissue, or a
258	3-layer arterial configuration, cannot be identified. In RPE cells arrayed along the sloping
259	sides of the calcified druse, lipofuscin becomes less electron-dense, smaller, and less
260	tightly packed (Figure 7E), in a smooth transition. These findings suggest
261	transdifferentiation, rather than ingestion of RPE organelles by invading phagocytes.
262	Next we consider tangled type 3 MNV (OD 1), for which en face OCTA (Figure
263	8A2) and OCT with flow overlay (Figure 8A3) shows persistent flow signal. Over time,
264	the extent of intraretinal fluid surrounding OD 1 in the INL and HFL fluctuates (Figure
265	8B2, Figure 8C2, respectively). Volume rendering of structural OCT and OCTA together
266	highlights flow within a hyperreflective lesion at the ONL and bacillary layer (Figure S9A,
267	Video S1). Inflow and outflow vessels can be connected to a superficial artery and vein,
268	respectively (Figure S9B&C). The RPE/BrM complex below the lesion is split by
269	hyporeflective material producing a double layer sign (Figure 7B2). ⁴⁰ Numerous HRF
270	are present in the INL (Figure 8C2).
271	Histologic analysis reveals components of tangled type 3 MNV (OD 1, Figure
272	8D) Magnified histology shows a vascular complex spanning 249 um horizontally

272 **8D**). Magnified histology shows a vascular complex spanning 249 μm horizontally,

273	extending into the superior perifovea (Figure S10). The complex is partly ensheathed by
274	collagenous material and flanked by intraretinal RPE cells. The INL/OPL border
275	subsides where the vascular lesion extends through the HFL/ONL (Figure S10C). The
276	ELM subsides at both edges of the calcified druse (yellow arrows in Figure S10B).
277	Bruch's membrane appears intact without evidence of a choroidal contribution to the
278	MNV lesions, or evidence of MNV contributing to the OCT double layer sign (Figure
279	S10A-C). Neovessels within the INL are moderately dilated, suggesting drainage
280	venules (Figure S10A). ⁴¹
281	To summarize, vascular geometry and thickness of the collagenous sheath
282	differentiates tangled versus pyramidal type 3 MNV. The sheath surrounding the tangled
283	complex is thin (Figure S10), and that surrounding pyramidal type 3 MNV is thick
284	(Figure 6). Otherwise, the two subtypes are comparable.
285	DRAMA, in the setting of anti-VEGF therapy
286	As shown below, all three instances of DRAMA (OS 1, OS 3, and OD 3) exhibit
287	mild hyperfluorescence on venous and recirculation phase FA 11 months before death.
288	In histology, all three localize above a horizontal ELM, signifying lack of atrophy.
289	OS 1 includes a vessel extending from the INL into the ONL (Figure 11A). Like
290	type 3 MNV lesions, this DRAMA lesion is located above a soft druse with BLamD and
291	altered RPE at its apex (Figure 11C). Unlike type 3 MNV, OS 1 does not have a
292	collagenous sheath, and the OPL does not subside (Figure 11C2).
293	Corresponding to FA, OCT of OS 3 shows an intraretinal hyperreflective,
294	stacked lesion, without intraretinal cysts (Figure 12A). Over time, a plume of HRF
295	extends nasally, still without evidence of cysts (Figure 12C). ^{42, 43} In histology, an RPE
296	tower atop a soft druse extends into the OPL (Figure 12D). This RPE complex
297	surrounds like a gripping hand a vessel extending downward from the DCP (Figure
298	13A&B). By light microscopy, the extending vessel in OS 3 resembles DRAMA OS 1 Page 13 of 32

299	(Figure 11) in its location above a soft druse with thick BLamD and a thinned RPE layer.
300	By transmission electron microscopy, OS 3 (Figure S14) resembles type 3 MNV lesions
301	but lacks a collagenous sheath. Endothelial cells in OS 3 lack fenestrations (Figure 13C),
302	like endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris
303	(Figure 13D&E) Other vessel wall components cannot be identified. The RPE complex
304	is multicellular, with some multinucleated cells (Figure S14). Organelle packing and
305	electron density is similar to in-layer RPE cells (not shown).
306	OCTA flow overlay of DRAMA OD 3 shows an intraretinal hyperreflective lesion
307	containing a pair of vascular outpouchings (Figure 15C). Corresponding histology
308	displays a pair of deeply descending vessels without significant intraretinal fluid (Figure
309	15D). Like type 3 MNV, the vessel complex of this DRAMA is ensheathed by a thin layer
310	of collagenous material and dives from the INL into the HFL (Figure 16A). Unlike type 3
311	MNV, the vessels do not extend past the HFL, and there is no subsidence of the ELM.
312	RPE organelles appear near the vessel complex (Figure 16B).
313	Vessel diameters of vascular lesions and comparison vessels
314	Table S3 shows internal and external vessel diameters of type 3 MNV and
315	DRAMA, as well as DCP vessels in the index case and donor eyes (8 intermediate AMD,
316	83.4 \pm 11.6 years; 8 controls, 84.1 \pm 6.7 years). Five of the 6 index case lesions are
317	noticeably larger (2.5-3-fold) than the comparison vessels. External vessel diameters of
318	type 3 MNV (OD 1, 15.02 μm ± 3.81 μm ; OD 2, 21.35 μm ± 10.79 μm ; OS 4 12.46 μm ±
319	0.95 $\mu m)$ are larger than nearby DCP diameters (7.18 μm ± 1.11 $\mu m).$ They are also
320	larger than vessel diameters in intermediate AMD (6.79 μm ± 1.05 $\mu m)$ and control (7.86
321	μm ± 1.47 $\mu m,$ Table S3A) eyes. In DRAMA, external vessel diameters of OS 1 and OS
322	3 (13.39 μm ± 2.68 $\mu m;$ 17.97 μm ± 1.08 $\mu m)$ are considerably larger than the
323	comparison vessels. A similar pattern is seen for internal vessel diameters (Table S3B).

Intraretinal vascular morphologies in treated AMD

- 324 An overview of unifying and distinguishing features of type 3 MNV and DRAMA,
- 325 combining this and prior reports, is provided in **Table 4**.^{3, 16, 24}

326

Intraretinal vascular morphologies in treated AMD

328 Discussion

329 In two anti-VEGF treated eves of one patient with neovascular AMD, we compare 330 longitudinal multimodal clinical imaging and histology of type 3 MNV and DRAMA (Table 331 2. Table 4). Although one patient, the clinical and imaging characteristics are typical of 332 multifocal type 3 MNV, including bilaterality (55% of cases)⁴⁴ and absence of type 1 MNV.^{11-13, 44, 45} Type 3 MNV is distinguished by intraretinal origin.^{1, 2, 46} frequent near-term 333 334 bilateral involvement,⁷⁻⁹ and significant choroidal thinning with reduced perfusion.^{47,48} 335 Patients with type 3 MNV are older at initial diagnosis than patients with type 1 MNV.^{49,50} 336 In our case, treated type 3 MNV has two morphologic phenotypes, pyramidal (OD 337 2, OS 4) or tangled (OD 1). All three analyzed complexes originate at the DCP and 338 extend posteriorly to approach persistent BLamD but do not enter the sub-RPE-BL 339 space or cross BrM. These two phenotypes may correspond to those seen by Borelli et 340 al in treatment-naïve type 3 MNV eyes with rotational three-dimensional OCTA. These 341 authors describe 26 lesions as 'filiform' and 9 lesions as 'saccular', which appear similar in shape to pyramidal (filiform) and tangled (saccular).¹⁴ We also find more pyramidal 342 343 lesions than tangled. It remains to be determined if saccular and filiform lesions differ in 344 spatial distribution and time of onset.¹⁴ 345 Our previous description of pyramidal Type 3 MNV included endothelial cells in a 346 thick collagenous matrix and dysmorphic RPE cells scattered along the neovascular 347 stalk. ¹⁶ OD2 and OS4 in this case ³ add pericytes plus a nearly continuous covering by highly pigmented RPE (OS4), supporting the early involvement of migratory RPE.^{2, 51} 348 349 The sheath distinguishes lesions from unaffected DCP vessels. The main differences 350 between pyramidal and tangled lesions are the larger horizontal extent and thinner 351 collagenous sheath of tangled.³ Endothelial cells of tangled vessels, and presumably

also those in pyramidal, lack fenestrations like the source vessels in the DCP.

353	As before, ¹⁶ we did not see vessels of choroidal origin in the sub-RPE-BL space,
354	as reported for advanced type 3 MNV. 14, 44, 52-54 Nor did we see DCP-originating vessels
355	penetrate through BLamD and enter the sub-RPE- BL space. This depth of penetration
356	was suggested as necessary for exudation.55 This proposal was based on OCTA
357	imaging without projection artifact removal to reduce spurious signal directly under type
358	3 MNV.55 Using volumetric artifact removal, we did not see OCTA flow signal in the sub-
359	RPE-BL space (Figure 8A3). It is possible that anti-VEGF treatment rendered invisible
360	downward projections from the DCP or upward projections from the choriocapillaris. We
361	think this is unlikely, because neo-capillaries may shrink after treatment, but they do not
362	disappear.56,57 Further, our use of stepped sections may miss key details. Nevertheless,
363	in all analyzed sections of this case, both BLamD and BrM were intact. Longitudinal
364	imaging before exudation onset is needed to understand this phase of type 3 MNV
365	progression.
365 366	progression. The thick collagenous sheath of type 3 MNV lesions may impact clinical
366	The thick collagenous sheath of type 3 MNV lesions may impact clinical
366 367	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of
366 367 368	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-
366 367 368 369	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-stage lesions regress completely while treatment of later-stage lesions require
366 367 368 369 370	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-stage lesions regress completely while treatment of later-stage lesions require continuing therapy. ^{2, 54} Further, treated type 3 MNV lesions can reappear after becoming
366 367 368 369 370 371	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-stage lesions regress completely while treatment of later-stage lesions require continuing therapy. ^{2, 54} Further, treated type 3 MNV lesions can reappear after becoming undetectable on OCTA. ^{55, 58} Lesions with thick sheaths remain detectable by structural
 366 367 368 369 370 371 372 	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-stage lesions regress completely while treatment of later-stage lesions require continuing therapy. ^{2, 54} Further, treated type 3 MNV lesions can reappear after becoming undetectable on OCTA. ^{55, 58} Lesions with thick sheaths remain detectable by structural OCT long after treatment. ⁵⁷ The collagenous neovascular stalk was populated by
 366 367 368 369 370 371 372 373 	The thick collagenous sheath of type 3 MNV lesions may impact clinical monitoring, as follows. All lesions responded to anti-VEGF with temporary resolution of exudation and persistence over several fluid absorption cycles. By OCTA, some early-stage lesions regress completely while treatment of later-stage lesions require continuing therapy. ^{2, 54} Further, treated type 3 MNV lesions can reappear after becoming undetectable on OCTA. ^{55, 58} Lesions with thick sheaths remain detectable by structural OCT long after treatment. ⁵⁷ The collagenous neovascular stalk was populated by endothelial cells and pericytes that either remained, self-renewed, or migrated in during

377	apparent regression, is influenced by sheaths, then monitoring for disease activity by
378	vascular characteristics in addition to fluid may be useful.
379	We showed that type 3 MNV can coexist with vascular formations that are
380	candidate precursors, early stages, and masqueraders for type 3 MNV. All three
381	DRAMA originated from the DCP and extended posteriorly into the HFL. None of the
382	DRAMA lesions involved the superficial capillary plexus, and no significant intraretinal
383	fluid was detectable on OCT over time. Like type 3 MNV (Figure 10), one DRAMA had
384	non-fenestrated endothelial cells and pericytes (Figure S14). Unlike type 3 MNV and like
385	native DCP, two DRAMA lacked a collagenous sheath. The one DRAMA with a thin
386	sheath (OD 3) also extended furthest of the three into the ONL, perhaps indicating
387	chronicity. Importantly, none of the DRAMA were accompanied by descent of the ELM,
388	the border of atrophy in neurosensory retina, although the ELM can be perforated by
389	inwardly migrating RPE as in OS 3. It is unlikely that DRAMA in our case represent
390	exudative or non-exudative perifoveal vascular anomalous complexes (ePVAC/
391	nePEVAC), ^{31,35,36} which typically appear above the DCP. Microvascular anomalies in
392	eyes with neovascular and non-neovascular AMD include capillary dilations and
393	telangiectasia that are associated with locally increased VEGF expression. $^{17,59-61}$ A
394	recent study showed that 19/94 eyes with type 3 MNV exhibited an asymptomatic
395	precursor stage on OCT. ⁴⁴ Because lack of exudation and non-progression to type 3
396	MNV in our case might result from VEGF suppression, ⁶² longitudinal imaging is required
397	to definitively place DRAMA in the progression sequence of type 3 MNV.
398	All analyzed vessels localized within 500-1500 μm of the foveal center, aligned
399	with similar findings for solitary and multifocal lesions. ^{11, 12} A role for choroidal ischemia
400	is hypothesized, $^{11, 63-65}$ because the choroid is thinner in eyes with type 3 MNV than in
401	eyes with types 1 and 2 MNV.66, 67 The radial symmetry of lesions around and close to
402	the fovea further suggests an association with the distribution of photoreceptors and Page 18 of 32

403	their support cells, which vary markedly in this eccentricity range. The ETDRS inner ring
404	of type 3 MNV vulnerability is just peripheral to the foveal avascular zone ³³ on the inner
405	slope of the crest of high rod density. Rod vision in AMD eyes is poorest in the same
406	area. 68-72 Metabolic demand of foveal cones is high, and choriocapillaris OCTA signal
407	decreases under the fovea throughout adulthood.73,74 It is thus possible that the
408	distribution of type 3 MNV is an additional effect of microvascular changes under the
409	fovea that also contribute to high-risk drusen and reduced sustenance of nearby rods.
410	Study strengths include the availability of OCTA with eye-tracked OCT,
411	volumetric projection artifact removal, rapid tissue preservation to largely maintain retinal
412	attachment, registration of pre-mortem and post-mortem OCT volumes, and
413	comprehensive histologic and microscopy techniques to reveal vessels and perivascular
414	tissue elements. Limitations include the lack of longitudinal OCTA imaging 9,75 and lack
415	of color fundus photography to reveal discoloration patterns typical of type 3 MNV. ¹⁴
416	Limitations to the laboratory study included use of stepped sections, lack of electron
417	microscopy for all lesions, and lack of immunohistochemistry to support cell type
418	identifications based on morphologic criteria. Finally, observations from one patient
419	however detailed cannot elucidate the full range of biologic variability.
420	Nevertheless, our study helped define morphologies of type 3 MNV and
421	proposed precursors that might guide future research, diagnosis, and disease monitoring.
422	The presence and extent of a collagenous sheath distinguishes type 3 MNV from normal
423	DCP vessels and may represent a stage in the evolution of DRAMA toward type 3 MNV.
424	Our hypotheses can be tested in the larger samples available in clinic populations and
425	clinical trial imaging datasets, ideally before onset of exudation.
426	

Intraretinal vascular morphologies in treated AMD

427 Acknowledgments

428

429 **Contribution statement**

- 430 All authors were involved in drafting the article or revising it critically for important
- 431 intellectual content, and all authors approved the final version to be published. Dr. Curcio
- 432 and Dr. Berlin had full access to all the data in the clinical picture and take responsibility
- 433 for the integrity of the data and the accuracy of the data analysis. Study conception and
- 434 design: AB, DC, LC, CB, RM, DF, KBF, CC. Acquisition of data: RM, CB, JM, LC, AB,
- 435 DC, KBF, CC. Analysis and interpretation of data: AB, DC, LC, DF, KBF, CC. Writing of
- 436 manuscript: AB, DC, CB, LC, RM, DF, KBF, CC.
- 437

438 **Financial support**

439 This work was supported by Genentech/ Hoffman LaRoche. The Macula Foundation, 440 Inc., New York, NY; unrestricted funds to the Department of Ophthalmology and Visual 441 Sciences (UAB) from Research to Prevent Blindness, Inc., and EyeSight Foundation of 442 Alabama. AB reports grants from the Dr. Werner Jackstädt-foundation. DC was 443 supported in part by a studentship from Fundação Luso-Americana para o 444 desenvolvimento (FLAD, USA R&D@PhD - Proj 2020/0140). Purchase of the slide 445 scanner was made possible by the Carl G. and Pauline Buck Trust. 446 The sponsors had no role in the design and conduct of the study: collection.

447 management, analysis, and interpretation of the data; preparation, review, or approval of

the manuscript; and decision to submit the manuscript for publication.

Intraretinal vascular morphologies in treated AMD

450 Financial disclosure

- 451 KBF is a consultant to Genentech, Zeiss, Heidelberg Engineering, Allergan, Bayer, and
- 452 Novartis. CAC receives research funds from Regeneron (outside this project). DF is an
- 453 employee of Genentech and a stockholder of Roche.
- 454

455 **Meeting presentation**

- 456 This work was submitted as part of an abstract to the annual meeting of The Association
- 457 for Research in Vision & Ophthalmology (ARVO) May 2021 and May 2022.
- 458
- 459
- 460
- 461
- 462

Intraretinal vascular morphologies in treated AMD

463 Figures

464 Figure 1. Multimodal retinal imaging of both eyes, 11 months before death.

- 465 **A** & **D**. Fluorescein angiography (FA) in venous (**A**) and recirculation phases (**D**) shows
- 466 multiple instances of hyperfluorescence. Vessels were found by histology at the green,
- 467 yellow, and fuchsia arrowheads in the right (**A**), and left eye (**D**). At the white arrowhead
- 468 in the left eye, no vessel could be found in histology.
- 469 **B** & **E**. Near-infrared reflectance imaging (NIR) shows reduced reflectance in areas of
- 470 angiographic leakage (arrowheads), possibly due to retinal edema. Soft drusen exhibit
- 471 hypo- and hyperreflective mottling. Scale bar 200 μm.
- 472 **C** & **F**. Fundus autofluorescence (FAF; λ_{ex} = 488 nm) highlights subretinal drusenoid
- 473 deposits especially superior to the fovea.
- 474 Lesion number, type, and spatial distribution are listed in **Table 2**.
- 475

476 Figure S2. Hyperfluorescence without histologic correlate, OS 2

- 477 A. Fluorescein angiography (FA, A1) venous phase, 11 months before death, shows
- 478 multiple instances of hyperfluorescence. An optical coherence tomography (OCT) B-
- scan (green line) displays drusen, a double-layer sign (white arrowhead), choroidal
- 480 hypertransmission, and hyperreflective foci (A2).
- 481 **B**, **C**. At 4 and 2 months before death, with 5 (**B**) and 6 (**C**) total injections, respectively,
- 482 the lesion is stable, without intraretinal cysts.
- 483

484 Figure S3. Initial presentation of right eye, 5 years before death

- 485 **A-E**. Fluorescein angiography (FA), near infrared reflectance images (NIR), and radial
- 486 optical coherence tomography (OCT) B-scans show exudative age-related macular
- 487 degeneration in the right eye at initial presentation. Based on these findings anti-VEGF488 therapy is initiated.
- 489 **A**. FA recirculation phase shows marked leakage. Corresponding OCT shows
- 490 intraretinal and subretinal hyporeflective cysts and spaces representing exudation,
- 491 located above drusenoid pigment epithelium detachments in the fovea and parafovea.
- 492 **B**. NIR and OCT show hyporeflective subretinal drusenoid deposits and hyperreflective
- 493 soft drusen across the macula. Hyperreflective foci are present in inner and outer
- 494 nuclear layer.
- 495

Intraretinal vascular morphologies in treated AMD

496 Figure S4. Initial presentation of left eye, 5 years before death

- 497 **A-E**. Near infrared reflectance images (NIR) and radial optical coherence tomography
- 498 (OCT) B-scans show non-exudative age-related macular degeneration in the left eye.
- 499 Hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen (B teal and
- 500 fuchsia arrowheads respectively) appear across the macula.
- 501 **B**. On the recirculation phase of fluorescein angiography (FA), no intraretinal or
- 502 subretinal fluid or leakage is present, ensuring absence of active MNV exudation.
- 503 **F**. A shallow RPE elevation with choroidal hypertransmission (white arrowhead) and
- 504 hyperreflective focus was stable on longitudinal follow-up by OCT (Figure S4). No
- 505 vessel was found in histology. This lesion presumably corresponds to a calcified druse.³⁹
- 506

Figure 5. Multimodal imaging, clinical course, and histology of pyramidal type 3MNV, OS 4.

- 509 **A**. Venous phase fluorescein angiography (FA, **A1**) shows mild leakage at site of type 3
- 510 MNV 11 months before death. Green lines on FA represent optical coherence
- 511 tomography (OCT) B-scans. Horizontal OCT B-scan (A2) displays a hyperreflective
- 512 lesion, hyperreflective foci (HRF), and small intraretinal cysts.
- 513 **B**. Blue lines on near-infrared reflectance (NIR, **B1**), represents histology section in **D**.
- 514 Radial OCT B-scan (B2) displays enlarged intraretinal cysts, after 5 total injections and 8
- 515 weeks following the prior injection. There is also subsidence of the outer plexiform layer
- 516 (OPL) and external limiting membrane (ELM).
- 517 **C**. On radial OCT B-scan (**C2**), intraretinal fluid is reduced after 6 injections and 6 weeks
- 518 following the prior injection. Numerous HRF are present in the inner nuclear layer (INL;
- 519 **C2;** scale bar 200 μm).
- 520 **D**. On histology, type 3 MNV is a pyramidal complex bounded by retinal pigment
- 521 epithelium cells. It extends from the INL/ OPL border to basal laminar deposit draping a
- 522 calcified druse. Structural damage to Henle's fiber layer at the right of the panel (green
- 523 asterisk) may indicate an area of prior intraretinal fluid. Magnified histology is shown in
- 524 **Figure 6**. Scale bar 100 μm.
- 525 Blue line, histology section. Time in months, time before death.

Intraretinal vascular morphologies in treated AMD

- 527 Figure 6. Pyramidal vascular complex in type 3 MNV, OS 4.
- 528 **A**, **B**. A pyramidal complex includes neovessels ensheathed by thick layers of
- 529 collagenous material and flanked by retinal pigment epithelium cells. The complex
- 530 extends from the inner nuclear layer (INL) through the outer plexiform layer, Henle fiber
- 531 layer, outer nuclear layer (OPL, HFL, ONL, respectively) and terminates at the basal
- 532 laminar deposits draping a calcified druse. Bruch's membrane appears intact with no
- 533 evidence of a choroidal contribution to the neovessel complex. The external limiting
- 534 membrane (ELM) descends at both sides of type 3 MNV base. There is some fluid at the
- 535 OPL-HFL border (yellow asterisk in B). Areas within dotted green boxes are shown in
- 536 **Figure 10**.
- 537

538 Figure 7. Transmission electron microscopy of pyramidal type 3 MNV, OS 4.

- 539 See Figure 8 for light microscopy of OS4. **A**. Neovessel with erythrocyte in the lumen
- 540 (blue asterisk) is ensheathed by endothelium, pericyte, and collagenous material (purple,
- 541 white, and black asterisks, respectively). Surrounding retinal pigment epithelium (RPE)
- 542 cells merge into multi-nucleated cells (red asterisk) or disperse into the Henle fiber layer
- 543 (HFL, green asterisk). Phagolysosomes are not visible in the RPE cells.
- 544 **B-D**. Endothelial cells in the neovessel and comparison vessels are displayed. The
- 545 lumen is located at the bottom of all panels.
- 546 **B**. No fenestrations are detected in the neovessel (orange arrowheads).
- 547 **C**. Fenestrations are visible in the choriocapillaris (orange arrowheads).
- 548 **D**. No fenestrations are detected in the deep capillary plexus (orange arrowheads).
- 549 E. Atop the calcified druse (fuchsia asterisk), RPE lipofuscin is more electron-dense at
- the druse base than at the druse top (left vs right in the panel). These changes are
- 551 consistent with transdifferentiation.
- 552

Figure 8. Multimodal imaging, clinical course, and histology of tangled type 3MNV, OD 1.

- 556 **A.** Green and red lines on near-infrared reflectance (NIR, **A1**) represent optical
- 557 coherence tomography (OCT) B-scans corresponding to en face OCT angiography
- 558 (OCTA, A2) and OCT B-scan with flow signal overlay (A3). After 29 total injections and 8
- 559 weeks following the prior injection (A2&A3), flow signal persists within the tangled
- 560 hyperreflective type 3 MNV lesion (green arrowhead). The RPE/Bruch's membrane

Intraretinal vascular morphologies in treated AMD

- 561 complex is split by hyporeflective material and appears as a "double layer" sign without 562 flow signal (A3). Red lines in A2 indicate the segmentation boundaries [outer plexiform 563 layer (OPL)-retinal pigment epithelium (RPE)] used to create the en face OCTA (A2). 564 **B.** Fluorescein angiography (FA, **B1**) shows late venous phase hyperfluorescence, after 565 32 total injections and 8 weeks following the last injection. OCT B-scan (B2) shows 566 intraretinal fluid in the inner nuclear and Henle fiber layers surrounding the type 3 MNV 567 lesion (green arrowhead). 568 C. NIR (C1) and radially oriented OCT B-scan (C2) shows intraretinal fluid adjacent to 569 the tangled type 3 MNV lesion (green arrowhead), after 36 total injections and 8 weeks 570 following the prior injection. Blue line in C1 represents histology section in panel D. 571 D. Panoramic histology shows a horizontally oriented tangled type 3 MNV lesion (green 572 arrowhead), partly bounded by RPE cells (scale bar 200 µm). The complex extends from 573 the inner nuclear layer border to a chipped out calcified druse, which correlates to the 574 double layer sign in B1. The druse is draped by basal laminar deposit and lacks RPE at 575 its apex. 576 Time in months, time before death; BCVA, best corrected visual acuity. 577 578 Figure 9. Volume rendering of structural optical coherence tomography (OCT, 579 gray) and OCT angiography (OCTA, yellow) of tangled type 3 MNV, OD 1. 580 **A**. Neovascular blood flow within a hyperreflective structure (white arrowheads) is 581 observed at the level of the outer nuclear layer (ONL). 582 **B**. Three-dimensional analysis of neovascular blood flow depict an anastomosis above
- 583 the retinal pigment epithelium (RPE)/ Bruch's membrane (BrM; green section) and a
- tangled structure connecting to the superficial artery (red arrow) and vein (blue arrow).
- 585 **C**. Volume rendering of OCTA with orthogonal structural sections evidence a tangled
- 586 neovascular lesion.
- 587

588 Figure S10. Tangled vascular complex in type 3 MNV, OD 1.

- 589 A-C. Tangled vascular complex (fuchsia arrowheads indicate lumen) spans 249 µm
- 590 horizontally towards the superior perifovea (**A**, 759 μm from fovea; **B**, 719 μm from fovea;
- 591 **C**, 552 µm from fovea). The complex is partly ensheathed by collagenous material and is
- 592 flanked by retinal pigment epithelium (RPE) cells. Two cells rest entirely within the outer
- 593 plexiform layer (OPL)/ inner nuclear layer (INL; light blue arrowhead in A). The INL/OPL
- subsides, and the vascular complex extends from the INL/OPL border through the Henle

Intraretinal vascular morphologies in treated AMD

- 595 fiber layer (HFL)/ outer nuclear layer (ONL). The complex adheres to basal laminar
- 596 deposits (BLamD) draping a calcified druse (d). Bruch's membrane (BrM) appears intact
- 597 without evidence of a choroidal contribution. The external limiting membrane (ELM)
- 598 descends at both edges of the calcified druse (yellow arrowheads in **B**). Vessel walls do
- 599 not exhibit obvious arterial or venous features. Vessel diameter within the INL was larger
- 600 than 15 µm, suggesting drainage venules.
- 601

602 Figure 11. Deep retinal age-related microvascular anomaly (DRAMA), OS1.

- 603 **A.** Near infrared reflectance (NIR) shows drusen and subretinal drusenoid deposits 11
- 604 months before death. Blue line, plane of histology section.
- 605 **B**. Fluorescein angiography (FA) recirculation phase shows minimal leakage at the site 606 of DRAMA.
- 607 **C.** On histology, a vessel extends downwards (yellow arrowheads) from the inner
- 608 nuclear layer (INL) into the outer plexiform layer (OPL) above a druse.
- 609

610 Figure 12. Multimodal imaging and histology of deep retinal age-related

- 611 microvascular anomaly (DRAMA) with intraretinal RPE complex, OS 3.
- 612
- 613 **A.** Fluorescein angiography (FA) venous phase shows faint staining, 11 months before
- death (A1). Optical coherence tomography (OCT, A2) shows a stack of intraretinal
- 615 hyperreflective foci (HRF, fuchsia arrowhead). No intraretinal cysts are visible.
- 616 **B.** After 6 total injections and 6 weeks following the prior injection, the stacked lesion
- 617 (fuchsia arrowhead) is stable, without cysts. A plume of HRF extend nasally 2 months
- 618 before death. Green lines, OCT B-scans; blue line, histology section.
- 619 **C.** On histology, a retinal pigment epithelium tower (fuchsia arrowhead) rises upward
- from a soft druse. Cells surround a vessel and extend into the outer plexiform layer.
- 621 Magnified histology is shown in **Figure 13**.
- 622

Figure 13. RPE complex associated with deep retinal age-related microvascular anomaly (DRAMA), OS 3.

- 625 **A**. A "hand" shaped complex consisting of retinal pigment epithelium (RPE) cells
- 626 surrounds vessel extending downward from the deep capillary plexus. Electron
- 627 microscopy of the area in the dotted fuchsia box is shown in **Figure S14**.

Intraretinal vascular morphologies in treated AMD

- 628 **B**. The RPE complex extends upward to the inner nuclear layer (INL). On either side of
- 629 this complex, there is no subsidence of outer plexiform layer (OPL) or external limiting
- 630 membrane (ELM), and the outer nuclear layer (ONL) is thinned. The complex emanates
- 631 from a continuous RPE layer over basal laminar deposit (BLamD) and a soft druse. The
- 632 druse is artifactually detached from Bruch's membrane (BrM).
- 633 **C-E**. Endothelial cell (EC) ultrastructure in DRAMA and comparison vessels are shown.
- 634 Vascular lumen is at the bottom of all panels.
- 635 **C.** No fenestrations are visible in the DRAMA (red blood cell, RBC).
- 636 **D.** No fenestrations are visible in the deep capillary plexus (pericyte, P).
- 637 **E.** Fenestrations are visible in the choriocapillaris endothelium (orange arrowheads;
- 638 white blood cell, WBC).
- 639

640 $\,$ Figure S14. Transmission electron microscopy of DRAMA with RPE complex, OS $\,$

- 641 **3.**
- 642 The Vessel is ensheathed by an endothelial (E) cell and a pericyte (P), with little
- 643 collagen. The Lumen contains a leukocyte (LC) and a red blood cell (RBC). The
- 644 surrounding tower of retinal pigment epithelium (RPE) is multicellular (white asterisk),
- 645 and multinucleated (fuchsia asterisks). RPE organelle packing density and electron-
- 646 density is similar to in-layer RPE cells (not shown).
- 647

648 Figure 15. Multimodal imaging of deep retinal age-related microvascular

- 649 anomalies (DRAMAs), OD 3.
- 650 **A.** Fluorescein angiography (FA) venous phase shows mild hyperfluorescence 11
- 651 months before death. B. Green and blue lines on near-infrared reflectance (NIR),
- represent optical coherence tomography (OCT) B-scan (C) and histology section (D). C.
- 653 Horizontally oriented OCT B-scan with OCT angiography (OCTA) flow overlay shows
- 654 cyst-like spaces in the Henle fiber layer adjacent to a pair of hyperreflective DRAMAs
- 655 (fuchsia arrowheads). The retinal pigment epithelium/Bruch's membrane complex to the
- left is split by hyporeflective material. **D**. OCTA shows a pair of intraretinal flow signals
- 657 (fuchsia arrowheads). **E.** Histology shows a pair of vessels extending from the inner
- nuclear layer border to the outer nuclear layer. Magnified histology is shown in Figure
- 659 **16**.
- 660

661	Figure 16. Vascular complex of deep retinal age-related microvascular anomaly
662	(DRAMA), OD 3.
663	
664	A, B. A penetrating pair of vessels, (DRAMAs, fuchsia arrowheads) ensheathed by
665	collagenous material dives from the inner nuclear layer (INL) into the Henle fiber layer
666	(HFL)/outer nuclear layer (ONL). Next to the vessels is a degenerative cyst in the Henle
667	fiber layer (HFL). There is no subsidence of external limiting membrane (ELM). The ONL
668	is thinned.
669	B . Retinal pigment epithelium (RPE) from the edge of a druse (d) migrates towards the
670	lower edge of the vessel complex, right side.
671	
672	
673	Video S1.
674	Volume rendering of structural OCT (gray) and OCTA (yellow) of tangled type 3
674 675	Volume rendering of structural OCT (gray) and OCTA (yellow) of tangled type 3 MNV, OD 1.
675	MNV, OD 1.
675 676	MNV, OD 1. The cube is rotated 180° to highlight vascular findings in the superior macula region.
675 676 677	MNV, OD 1.The cube is rotated 180° to highlight vascular findings in the superior macula region.Coronal view demonstrates blood flow immediately below the deep capillary plexus level
675 676 677 678	 MNV, OD 1. The cube is rotated 180° to highlight vascular findings in the superior macula region. Coronal view demonstrates blood flow immediately below the deep capillary plexus level in two separate areas. Superposition with structural OCT (gray channel) demonstrates
675 676 677 678 679	 MNV, OD 1. The cube is rotated 180° to highlight vascular findings in the superior macula region. Coronal view demonstrates blood flow immediately below the deep capillary plexus level in two separate areas. Superposition with structural OCT (gray channel) demonstrates neovascular blood flow within an hyperreflective structure at the outer nuclear layer and
675 676 677 678 679 680	MNV, OD 1. The cube is rotated 180° to highlight vascular findings in the superior macula region. Coronal view demonstrates blood flow immediately below the deep capillary plexus level in two separate areas. Superposition with structural OCT (gray channel) demonstrates neovascular blood flow within an hyperreflective structure at the outer nuclear layer and above Bruch's membrane (BrM). The superficial arteries (red) and veins (blue) in the
675 676 677 678 679 680 681	MNV, OD 1. The cube is rotated 180° to highlight vascular findings in the superior macula region. Coronal view demonstrates blood flow immediately below the deep capillary plexus level in two separate areas. Superposition with structural OCT (gray channel) demonstrates neovascular blood flow within an hyperreflective structure at the outer nuclear layer and above Bruch's membrane (BrM). The superficial arteries (red) and veins (blue) in the vicinity of the lesion are outlined after fluorescein angiography analysis. Three-

Intraretinal vascular morphologies in treated AMD

References

- 1. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30(9):1333-49.
- 2. Su D, Lin S, Phasukkijwatana N, et al. An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 2016;36:S40-S9.
- 3. Berlin A, Cabral D, Chen L, et al. Correlation of Optical Coherence Tomography Angiography of Type 3 Macular Neovascularization With Corresponding Histology. JAMA Ophthalmol. 2022;140(6):628-633.
- 4. Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 2020;127(5):616-36.
- 5. Yannuzzi LA, Negrão S, Tomohiro I, et al. Retinal angiomatous proliferation in agerelated macular degeneration. Retina 2012;32:416-34.
- 6. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. American Journal of Ophthalmology 2014;158(4):769-79. e2.
- 7. Kim JH, Kim JW, Kim CG, Lee DW. Influence of fellow-eye examination interval on visual acuity at fellow-eye neovascularization in unilateral type 3 neovascularization. Retina 2020;40(7):1255-61.
- 8. Kwak JH, Park WK, Kim RY, et al. Unaffected fellow eye neovascularization in patients with type 3 neovascularization: Incidence and risk factors. PIoS One 2021;16(7):e0254186.
- 9. Sacconi R, Forte P, Capuano V, et al. OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients. Retina 2022:10.1097.
- 10. Freund KB, Ho I-V, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28(2):201-11.
- 11. Najeeb BH, Deak G, Schmidt-Erfurth U, Gerendas BS. The RAP study, report two: the regional distribution of macular neovascularization type 3, a novel insight into its etiology. Retina 2020;40(12):2255-62.
- 12. Haj Najeeb B, Deak GG, Sacu S, et al. The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3. Graefe's Archive for Clinical and Experimental Ophthalmology 2022;260(1):141-7.
- Haj Najeeb B, Deak GG, Schmidt-Erfurth U, Gerendas BS. The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3. Acta Ophthalmologica 2021.
- 14. Borrelli E, Sacconi R, Klose G, et al. Rotational three-dimensional OCTA: a notable new imaging tool to characterize type 3 macular neovascularization. Scientific Reports 2019;9(1):1-8.
- 15. Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathological findings of retinal angiomatous proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology 2007;245(2):295-300.
- 16. Li M, Dolz-Marco R, Messinger JD, et al. Clinicopathologic Correlation of Anti– Vascular Endothelial Growth Factor–Treated Type 3 Neovascularization in Age-Related Macular Degeneration. Ophthalmology 2018;125(2):276-87.
- 17. Sacconi R, Freund KB, Yannuzzi LA, et al. The expanded spectrum of perifoveal exudative vascular anomalous complex. American Journal of Ophthalmology 2017;184:137-46.
- 18. Gilani F, Gal-Or O, Freund KB. Spontaneous rupture and involution of a "macromicroaneurysm" in diabetic retinopathy. Retina 2017;37(6):e73-e4.
- 19. Spaide RF, Barquet LA. Retinal capillary macroaneurysms. Retina 2019;39(10):1889-95.
- 20. Sacconi R, Cohen SY, Borrelli E, et al. Correspondence. Retina 2019;39(11):e48-e9. Page 29 of 32

- 21. Spaide RF. Correspondence Reply. Retina 2019;39(11):E49-E50.
- 22. Sacconi R, Borrelli E, Sadda S, et al. Nonexudative perifoveal vascular anomalous complex: the subclinical stage of perifoveal exudative vascular anomalous complex? American Journal of Ophthalmology 2020;218:59-67.
- 23. Querques G, Kuhn D, Massamba N, et al. Perifoveal exudative vascular anomalous complex. Journal Français d'Ophtalmologie 2011;34(8):559. e1-. e4.
- 24. Cabral D, Ramtohul P, Fradinho A, Freund KB. Volume Rendering of Deep Retinal Age-Related Microvascular Anomalies. Ophthalmol Retina 2022.
- 25. Chen L, Messinger JD, Sloan KR, et al. Nonexudative macular neovascularization supporting outer retina in age-related macular degeneration: a clinicopathologic correlation. Ophthalmology 2020;127(7):931-47.
- 26. Querques G, Querques L, Forte R, et al. Precursors of type 3 neovascularization: a multimodal imaging analysis. Retina 2013;33(6):1241-8.
- 27. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310(20):2191-4.
- 28. Edemekong P, Annamaraju P, Haydel M. Health Insurance Portability and Accountability Act. StatPearls Treasure Island (FL): StatPearls Publishing 2021.
- 29. Rocholz R, Teussink M, Dolz-Marco R, et al. SPECTRALIS optical coherence tomography angiography (OCTA): principles and clinical applications. Heidelb Eng Acad 2018(September):1-10.
- 30. Cabral D, Fradinho AC, Pereira T, et al. Macular Vascular Imaging and Connectivity Analysis Using High-Resolution Optical Coherence Tomography. Translational Vision Science & Technology 2022;11(6):2-.
- 31. Breazzano MP, Bacci T, Curcio CA, Freund KB. Novel multimodal imaging and volume rendering of type 3 macular neovascularization. Retina 2020;40(10):e55-e7.
- 32. Xu X, Yannuzzi NA, Fernández-Avellaneda P, et al. Differentiating veins from arteries on optical coherence tomography angiography by identifying deep capillary plexus vortices. American Journal of Ophthalmology 2019;207:363-72.
- 33. Kim JH, Chang YS, Kim JW, et al. Characteristics of type 3 neovascularization lesions: focus on the incidence of multifocal lesions and the distribution of lesion location. Retina 2020;40(6):1124-31.
- 34. Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 1991;98(5):786-806.
- 35. Pongsachareonnont P, Somkijrungroj T, Assavapongpaiboon B, et al. Foveal and parafoveal choroidal thickness pattern measuring by swept source optical coherence tomography. Eye 2019;33(9):1443-51.
- 36. Balaratnasingam C, An D, Sakurada Y, et al. Comparisons between histology and optical coherence tomography angiography of the periarterial capillary-free zone. American Journal of Ophthalmology 2018;189:55-64.
- 37. Litts KM, Messinger JD, Dellatorre K, et al. Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration. JAMA Ophthalmology 2015;133(5):609-12.
- 38. Balaratnasingam C, An D, Freund KB, et al. Correlation between histologic and OCT angiography analysis of macular circulation. Ophthalmology 2019;126(11):1588-9.
- 39. Berlin A MJ, Ferrara D, Freund KB, Curcio CA. OCT features relevant to neovascular AMD management and non-neovascular AMD progression: clinicopathologic correlation. Retinal Cases and Brief Reports 2022 ; 9900:10.1097.
- 40. Berlin A, Chen L, Messinger J, et al. Double-layer sign in neovascular age-related macular degeneration–do we treat? Acta Ophthalmologica 2022;100(3):348-9.
- 41. Snodderly DM, Weinhaus RS, Choi J. Neural-vascular relationships in central retina of macaque monkeys (Macaca fascicularis). Journal of Neuroscience 1992;12(4):1169-93.
- 42. Balaratnasingam C, Messinger JD, Sloan KR, et al. Histologic and optical coherence tomographic correlates in drusenoid pigment epithelium detachment in age-related macular degeneration. Ophthalmology 2017;124(5):644-56.

- 43. Cao D, Leong B, Messinger JD, et al. Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium. Investigative Ophthalmology & Visual Science 2021;62(10):34-.
- 44. Najeeb BH, Deak GG, Mylonas G, et al. The RAP study, report 5: rediscovering macular neovascularization Type 3: multimodal imaging of fellow eyes over 24 months. Retina 2022;42(3):485.
- 45. Najeeb BH, Deak GG, Schmidt-Erfurth UM, Gerendas BS. RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3. British Journal of Ophthalmology 2021;105(1):113-7.
- 46. Querques G, Souied EH, Freund KB. How has high-resolution multimodal imaging refined our understanding of the vasogenic process in type 3 neovascularization? Retina 2015; 35(4):603-13.
- 47. Borrelli E, Souied EH, Freund KB, et al. Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration. Retina 2018;38(10):1968-76.
- 48. Koizumi H, lida T, Saito M, et al. Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(4):515-20.
- 49. Caramoy A, Ristau T, Lechanteur YT, et al. Environmental and genetic risk factors for retinal angiomatous proliferation. Acta Ophthalmologica 2014;92(8):745-8.
- 50. Daniel E, Shaffer J, Ying G-s, et al. Outcomes in eyes with retinal angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2016;123(3):609-16.
- 51. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110(2):392-9.
- 52. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008; 28(3):375-84
- 53. Cho HJ, Lim SH, Kim J, et al. Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Graefe's Archive for Clinical and Experimental Ophthalmology 2021:1-9.
- 54. Kim JH, Chang YS, Kim JW, et al. Difference in treatment outcomes according to optical coherence tomography–based stages in type 3 neovascularization (retinal angiomatous proliferation). Retina 2018;38(12):2356-62.
- 55. Sacconi R, Battista M, Borrelli E, et al. OCT-A characterisation of recurrent type 3 macular neovascularisation. British Journal of Ophthalmology 2021;105(2):222-6.
- 56. Huang D, Jia Y, Rispoli M, et al. OCT angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. Retina 2015;35(11):2260.
- 57. Skalet AH, Miller AK, Klein ML, et al. Clinicopathologic correlation of retinal angiomatous proliferation treated with ranibizumab. Retina 2017;37(8):1620.
- 58. Han JW, Cho HJ, Kang DH, et al. Changes in optical coherence tomography angiography and disease activity in type 3 neovascularization after anti–vascular endothelial growth factor treatment. Retina 2020;40(7):1245-54.
- 59. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103(11):1820-8.
- 60. Tolentino MJ, Mcleod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. American Journal of Ophthalmology 2002;133(3):373-85.
- 61. Jackson TL, Danis RP, Goldbaum M, et al. Retinal vascular abnormalities in neovascular age-related macular degeneration. Retina 2014;34(3):568-75.
- 62. Spaide RF. New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. Retina 2019;39(8):1451-64.

- 63. Hayreh SS. Segmental nature of the choroidal vasculature. British Journal of Ophthalmology 1975;59(11):631-48.
- 64. Hayreh SS. In vivo choroidal circulation and its watershed zones. Eye 1990;4(2):273-89.
- 65. Hayreh SS. Posterior ciliary artery circulation in health and disease the Weisenfeld lecture. Investigative Ophthalmology & Visual Science 2004;45(3):749-57.
- 66. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 2014;34(7):1316-22.
- 67. Kim JH, Kim JR, Kang SW, et al. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. American Journal of Ophthalmology 2013;155(4):743-9. e2.
- 68. Tan R, Guymer RH, Luu CD. Subretinal drusenoid deposits and the loss of rod function in intermediate age-related macular degeneration. Investigative Ophthalmology & Visual Science 2018;59(10):4154-61.
- 69. Tan RS, Guymer RH, Aung K-Z, et al. Longitudinal assessment of rod function in intermediate age-related macular degeneration with and without reticular pseudodrusen. Investigative Ophthalmology & Visual Science 2019;60(5):1511-8.
- 70. Chen KG, Alvarez JA, Yazdanie M, et al. Longitudinal study of dark adaptation as a functional outcome measure for age-related macular degeneration. Ophthalmology 2019;126(6):856-65.
- 71. Zhang Y, Sadda SR, Sarraf D, et al. Spatial Dissociation of Subretinal Drusenoid Deposits and Impaired Scotopic and Mesopic Sensitivity in AMD. Investigative Ophthalmology & Visual Science 2022;63(2):32-.
- 72. Nigalye AK, Hess K, Pundlik SJ, et al. Dark Adaptation and Its Role in Age-Related Macular Degeneration. Journal of Clinical Medicine 2022;11(5):1358.
- 73. Zheng F, Zhang Q, Shi Y, et al. Age-dependent changes in the macular choriocapillaris of normal eyes imaged with swept-source optical coherence tomography angiography. American Journal of Ophthalmology 2019;200:110-22.
- 74. Ingram NT, Fain GL, Sampath AP. Elevated energy requirement of cone photoreceptors. Proceedings of the National Academy of Sciences 2020;117(32):19599-603.
- 75. Borrelli E, Mastropasqua L, Souied E, et al. Longitudinal assessment of type 3 macular neovascularization using three-dimensional volume-rendering optical coherence tomography angiography. Canadian Journal of Ophthalmology 2021.




















this version posted January 20, 2023. The copyright holder for this preprint honas granted medRxiv a license to display the preprint in perpetuity. medRxiv preprin (which was) g/10.1101/202 er review) is th i: htt Áll rights 10 * 10 µm B C D EC EC RBC RBC WBC 1 µm Ε 10 µm



medRxiv preprint doi: https://doi.org/10.1101/2022.09.13.22279910; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprindoi: https://doi.org/10.1101/2022.09.13.22279910; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2022.09.13.22279910; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







medRxiv preprint doi: https://doi.org/10.1101/2022.09.13.22279910; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.









1 Table S1. Content of imaging data pieces

figure number as appearing	Laterality and lesion number	Lesion type	Content	Title
1	NA	NA	multimodal imaging	Multimodal retinal imaging of both eyes, 11 months before death ≧
S2	OS2	type 3 MNV	Clinicopathologic correlation, panoramic histology	Title Multimodal retinal imaging of both eyes, 11 months before death Hyperfluorescence without histologic correlate, OS2. Initial presentation of right eye, 5 years before death Initial presentation of left eye, 5 years before death Multimodal imaging, clinical course, and histology of pyramidat type 3 MNV, OS4.
S 3	NA	NA	clinical imaging baseline	Initial presentation of right eye, 5 years before death
S 4	NA	NA	clinical imaging baseline	Initial presentation of left eye, 5 years before death
5	OS4	type 3 MNV	Clinicopathologic correlation, panoramic histology	Multimodal imaging, clinical course, and histology of pyramidal type 3 MNV, OS4. Pyramidal vascular complex in type 3 MNV, OS4.
6	OS4	type 3 MNV	Magnified histology	Pyramidal vascular complex in type 3 MNV, OS4.
7	OS4	type 3 MNV	Transmission electron microscopy	Transmission electron microscopy of pyramidal type 3 MNV, OS4 Multimodal imaging, clinical course, and histology of tangled
8	OD1	type 3 MNV	MNV Clinicopathologic Multimodal imaging, clinical course, and histology of tangled correlation, type 3 MNV, OD1. panoramic histology	
S9	OD1	type 3 MNV	3D Volume rendering	Volume rendering of structural optical coherence tomography (OCT, gray) and OCT angiography (OCTA, yellow) of tangled type 3 MNV, OD1.
S10	OD1	type 3 MNV	Magnified histology	Tangled vascular complex in type 3 MNV, OD1.

					was
11	OS1	DRAMA/ type 3 MNV precursor	Clinicopathologic correlation, panoramic histology	Deep retinal age-related microvascular anomaly (DRAMA), OS1.	s not certified by peer
12	OS3	DRAMA/ type 3 MNV precursor	Clinicopathologic correlation, panoramic histology	Multimodal imaging and histology of deep retinal age-related microvascular anomaly (DRAMA) with intraretinal RPE complex, OS3.	
13	OS3	DRAMA/ type 3 MNV precursor	Magnified histology & Transmission electron microscopy	RPE complex associated with deep retinal age-related microvascular anomaly (DRAMA), OS3.	review) is the author/funder, All rights reserved. No
S14	OS3	DRAMA/ type 3 MNV precursor	Transmission electron microscopy	Transmission electron microscopy of DRAMA with RPE complex, OS3.	who ha
15	OD3	DRAMA/ type 3 MNV precursor	Clinicopathologic correlation, panoramic histology	Multimodal imaging of deep retinal age-related microvascula anomalies (DRAMAs), OD3.	lowed without
16	OD3	DRAMA/ type 3 MNV precursor	Magnified histology	Vascular complex of deep retinal age-related microvascular anomaly (DRAMA), OD3.	Rxiv a license t permission.

T3MNV, type 3 macular neovascularization; DRAMA, deep retinal age-related microvascular anomaly; OD, right eye; OS, left eye.

Table 2. Spatial distribution and vascular lesion types in two eyes of the index case.

Eye, lesion number,	ETDRS	Lesion type	intravitreal	Analysis
color in <u>Fig. 1</u>	ring & sector		anti-VEGF	
OD 1 (green)	Inner, S	T3MNV, tangled	37	LM
OD 2 (yellow)	Inner, N	T3MNV, pyramidal	37	LM
OD 3 (fuchsia)**	Inner, T	DRAMA	37	LM
OS 1 (yellow)	Inner, S	DRAMA	6	LM
OS 2 (white)	Outer, I	not found	6	n.a.
OS 3 (fuchsia)	Inner, I	DRAMA	6	LM, EM
OS 4 (green)	Inner, N	T3MNV, pyramidal	6	LM, EM

T3MNV, type 3 macular neovascularization; DRAMA, deep retinal age-related microvascular anomaly; LM, light microscopy; EM, electron microscopy. OD, right eye; OS, left eye.

ETDRS sectors (delimited by 45° lines): S, superior; I, inferior; N. nasal; T, temporal

Within each eye, lesions seen on fluorescein angiography were numbered clockwise, starting at 12:00 (ETDRS grid superior sector).

* Span width of tangled vascular lesion: 520-769 µm; ** pair of vascular lesions.

Table S3. Diameters of vessels in histology

	T3 MNV*			DRAMA*			T3 DCP [†]	Control [†]	AMD [†]
	OD 1	OD 2	OS 4	OS 1	OS 3	OD 3			
Mean	15.02	21.35	12.46	13.39	17.97	8.62	7.18	7.86	6.79
SD	3.81	10.79	0.95	2.68	1.08	1.05	1.11	1.47	1.05

A External vessel diameter (um)

B. Internal vessel diameter (µm)

	T3 MNV*	-		DRAMA*			T3 DCP [†]	Control [†]	AMD ^{††}
	OD 1	OD 2	OS 4	OS 1	OS 3	OD 3			
Mean	9.34	14.86	9.87	9.40	8.28	5.17	3.69	4.44	3.75
SD	1.85	6.19	0.76	2.00	0.31	0.34	0.92	0.98	0.92

* 3 to 6 measurements for each; T3 MNV, type 3 macular neovascularization; DRAMA, deep retinal age-related microvascular anomaly.

[†] 8 female control eyes (84.1 ± 6.7 years; 1 male and 7 female), intermediate AMD eyes (83.4 ± 11.6 years). Histology from Project MACULA <u>https://projectmacula.org</u>. Number of measurements, Type 3 DCP (n=123); Controls (n=88); AMD (n=107). OS2 no lesion identified in histology.

Feature	Type 3 MNV pyramidal	Type 3 MNV tangled	DRAMA		
Location, topographic	ETDRS inner	ETDRS inner	ETDRS inner		
Location, layer	HFL/ONL	HFL/ONL	HFL/ONL		
RPE	Absent, scattered, migrated	Absent, scattered, migrated	Migrated, intact		
ELM	descent	descent	horizontal		
Sub-RPE-BL space	End-stages of soft drusen*	End-stages of soft drusen*	Soft drusen, cells		
Originating plexus	DCP	DCP	DCP		
Shape of vascular complex	Compact, base-down pyramid	Vertical, horizontally spreading	Downward extending loop		
Structure over time	dynamic	dynamic	stable ²⁴		
Pericytes	Yes	Yes	Yes		
Exudation	Yes	Yes	No		
Anti-VEGF response	Yes	Yes	No		
Collagenous sheath	Thick	Thin	None/thin if advanced		
Endothelium	Non-fenestrated	Non-fenestrated	Non-fenestrated		

Table 4. Features of Type 3 MNV and DRAMA compared

*Calcific nodules, cells (subducted RPE, macrophages, giant cells, fibroblasts), Müller glia, avascular fibrosis Based on current and published data. ^{3, 16, 24}